Core Viewpoint - Cinda Biologics (01801) shares rose nearly 3%, currently up 2.2% at HKD 83.6, with a trading volume of HKD 204 million [1] Group 1: Company Developments - Cinda Biologics announced that its anti-GPRC5D/BCMA/CD3 trispecific antibody IBI3003 received Fast Track Designation from the U.S. FDA on January 27, 2026 [1] - The intended indication for IBI3003 is for relapsed or refractory multiple myeloma (R/R MM) patients who have undergone at least four lines of treatment, including a proteasome inhibitor (Pl), an immunomodulatory drug (IMiD), and an anti-CD38 monoclonal antibody [1] - IBI3003 is developed using Cinda Biologics' proprietary Sanbody platform and is currently undergoing Phase I/II clinical trials in China, Australia, and soon in the U.S. to explore its efficacy and safety in R/R MM [1]
信达生物涨近3% IBI3003获美国FDA快速通道资格认定 治疗多发性骨髓瘤